This episode of The Nordic Venture Show podcast features Fuse Vectors - a company focused on revolutionizing gene therapy through its innovative cell-free viral vector technology. Their primary goal is to overcome the limitations of current Adeno-Associated Virus (AAV) production methods, which they identify as inefficient, costly, and potentially toxic. Fuse Technology aims to provide a superior alternative that ensures high purity and simplifies the manufacturing process. By offering their platform and services, Fuse Vectors intends to accelerate the development of safer and more effective gene therapies, ultimately broadening access to these treatments for individuals with genetic illnesses.